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Abstract : Drug-tolerant cells are mediators of acquired resistance. BIM-intron2 deletion polymorphism (BIM-
del) is one of the mechanisms underlying the resistance to epidermal growth factor tyrosine kinase inhibitor 
(EGFR-TKI)-mediated apoptosis that induces drug tolerance. Here, we investigated whether resminostat, a his-
tone deacetylase inhibitor, circumvents BIM-del-associated apoptosis resistance. The human EGFR-mutated 
non-small cell lung cancer (NSCLC) cell line PC-9 and its homozygous BIM-del-positive variant (PC-9 BIMi2- / -), 
established by editing with zinc finger nuclease, were used. In comparison with PC-9 cells, PC-9 BIMi2- / - cells 
were less sensitive to apoptosis mediated by EGFR-TKIs such as gefitinib and osimertinib. The combined use of 
resminostat and an EGFR-TKI preferentially induced the expression of the pro-apoptotic BIM transcript con-
taining exon 4 rather than that containing exon 3, increased the level of pro-apoptotic BIM protein (BIMEL), and 
stimulated apoptosis in vitro. In a subcutaneous tumor model derived from PC-9 BIMi2- / - cells, gefitinib monothera-
py decreased tumor size but retained residual lesions, indicative of the presence of tolerant cells in tumors. The 
combined use of resminostat and gefitinib increased BIMEL protein level and induced apoptosis, subsequently 
leading to the remarkable shrinkage of tumor. These findings suggest the potential of resminostat to circumvent 
tolerance to EGFR-TKIs associated with BIM deletion polymorphism. J. Med. Invest. 67 : 343-350, August, 2020
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INTRODUCTION
 
Non-small cell lung cancer (NSCLC) with classical epidermal 
growth factor receptor (EGFR) mutations such as exon 19 deletion 
and L858R point mutation is highly sensitive to EGFR tyrosine 
kinase inhibitors (EGFR-TKIs), including the first-generation 
inhibitor gefitinib and the third-generation inhibitor osimertinib 
(1, 2). However, almost all patients experience disease recur-
rence, owing to the acquired resistance to EGFR-TKIs. Recent 
studies have revealed the presence of a small population of cells 
that adapts to the initial treatment with EGFR-TKIs as persist-
ers, which form the basis for acquired resistant lesions (3). Eluci-
dation of the adaptation mechanism following initial treatment 
with EGFR-TKIs may allow development of novel initiation 
therapies to eradicate tumor cells and improve the therapeutic 
outcome in advanced EGFR-mutated NSCLC by preventing the 
development of acquired resistance.
The decrease in the activity of BIM, also known as Bcl-2-like 
protein 11, a pro-apoptotic molecule that belongs to the Bcl-2 
family, has been recognized as one of mechanisms underlying 
the intrinsic resistance or tolerance to EGFR-TKIs. BIM ex-
pression upregulation is essential for the induction of apoptosis 
in NSCLC cells carrying EGFR mutations following treatment 
with first- to third-generation EGFR-TKIs. On the contrary, 
low BIM protein level is associated with resistance or tolerance 
to EGFR-TKIs (4, 5). A functional BIM deletion polymorphism, 
specifically a 2,903 bp deletion in intron 2, was reported in East 
Asian individuals (13%–18%) (6) and South American patients 
with NSCLC (15.7%) (7) and was associated with poor response 
to EGFR-TKIs (6, 8). Mechanistically, BIM deletion results in 
the mutually exclusive splicing of exon 3 over the BH3-encod-
ing (pro-apoptotic) exon 4 of the BIM pre-mRNA, leading to the 
production of an inactive BIM protein isoform (BIMγ). This 
protein lacks the BH3 domain, and its production results in the 
reduction in the expression of the pro-apoptotic BIM protein 
isoform (BIMEL) in EGFR-mutant lung cancer cell lines upon 
TKI exposure, thereby inducing TKI resistance (6). Several me-
ta-analyses have reported an association between BIM deletion 
polymorphism and shorter progression-free survival (PFS) in 
patients with NSCLC carrying EGFR mutations who received 
either gefitinib or erlotinib (9-14). Therefore, the restoration of 
BIM activity may be an important strategy to overcome the 
intrinsic resistance or tolerance to EGFR-TKI in patients with 
EGFR-mutated NSCLC with BIM deletion.
Histone deacetylase (HDAC) is one of the targets for cancer 
treatment. For instance, vorinostat (suberoylanilide hydroxamic 
acid [SAHA]) is a small molecule inhibitor of pan HDACs that 
targets both class I HDACs (HDAC-1, 2, 3, and 8) and class IIb 
HDACs (HDAC-6 and 10), causes acetylation of histone proteins, 
and induces cell differentiation, cell cycle arrest, and apoptosis 
in several types of tumor cells (15). Vorinostat monotherapy has 
been approved for cutaneous T-cell lymphoma. We have previ-
ously reported that the combination of vorinostat and gefitinib 
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could preferentially induce the transcription of the pro-apoptotic 
exon 4-containing BIM isoform over that of the inactive exon 
3-containing isoform, thereby resensitizing the BIM deletion-con-
taining EGFR-mutated NSCLC cell lines to TKIs in vitro and in 
vivo (16). Based on our preclinical findings, we performed a phase 
I study, VICTORY-J, in patients with EGFR-mutated NSCLC 
harboring BIM deletion polymorphism to evaluate the safety of 
the combined therapy with vorinostat and gefitinib. Vorinostat at 
400 mg / day biweekly combined with gefitinib 250 mg / day was 
the recommended dose in phase II studies (17). As panobinostat, 
another pan-HDAC inhibitor, has been recently approved for 
multiple myeloma (18), newer generations of HDAC inhibitors 
are currently under development. 
Resminostat is a potent inhibitor of class I, IIb, and IV HDACs. 
It induces hyperacetylation of histone H4 in multiple myeloma 
cells (19). Safety and efficacy of resminostat were evaluated in 
various clinical studies for hepatocellular carcinoma, non-small 
cell lung cancer, biliary tract cancer and Hodgkin’s lymphoma 
(20-24). Its activity is being evaluated in a clinical trial (25). In 
the present study, we examined the effect of resminostat on the 
susceptibility of EGFR-mutated NSCLC cell lines with BIM dele-
tion polymorphism to an EGFR-TKI in vitro and in vivo. 
MATERIALS AND METHODS
Cell lines and reagents
PC-3 cells, derived from a Japanese female patient with 
NSCLC carrying an exon 19 deletion in EGFR and differing 
from the prostate cancer cell line PC-3 (ATCC CRL1435), were 
purchased from the Human Science Research Resource Bank. 
The NSCLC cell line, PC-9 carrying EGFR mutations, was ob-
tained from the RIKEN Cell Bank (Ibaraki, Japan). PC-9 cells 
with a homozygous BIM-intron 2 deletion polymorphism (PC-9 
BIM i2-/-) were established by editing with zinc finger nuclease, 
as previously reported (26). PC-9 GXR cells carrying deletions 
in the EGFR exon 19 and T790M mutation were established at 
Kanazawa University (Kanazawa, Japan) from PC-9 cell xeno-
graft tumors in nude mice that had acquired resistance to gefi-
tinib (27). PC-3 and the other three cell lines were maintained 
in Dulbecco’s modified Eagle’s medium (DMEM) and Roswell 
Park Memorial Institute (RPMI)-1640 medium, respectively, 
both supplemented with 10% fetal bovine serum (FBS) and 
antibiotics. Resminostat was produced by Yakult Honsha Co., 
Ltd (Tokyo, Japan). Gefitinib, osimertinib, and vorinostat were 
obtained from Selleck Chemicals (Houston, TX). 
Genotype and expression analysis of BIM
Genomic DNA was extracted from cells using a Maxwell 
16 Tissue DNA Purification Kit on a Maxwell 16 Instrument 
(Promega) according to manufacturer’s instructions. To recog-
nize the presence of the wild-type and deletion polymorphism al-
leles, we conducted polymerase chain reactions (PCR) using the 
discriminating primers (forward 5′-AATACCACAGAGGCCCA-
CAG-3′ and reverse 5′-GCCTGAAGGTGCTGAGAAAG-3′). 
Genomic DNAs were amplified using a Veriti Thermal Cy-
cler (Applied Biosystems) with REDAccuTaq LA DNA Poly-
merase (Sigma). The PCR amplicons for the wild-type (4226 
bp) and deletion (1323 bp) alleles were separated by agarose gel 
electrophoresis.
RNA interference
The cells (2 × 105 cells / well) cultured in a medium containing 
10% FBS (antibiotic-free) for 24 h were treated with a Stealth 
RNAi small-interfering RNA (siRNA) against BIM and Stealth 
RNAi siRNA Negative Control Lo GC (Invitrogen) using Lipo-
fectamine RNAiMAX (Invitrogen) for 48 h.
Western blot analysis
Western blotting was conducted using antibodies against 
phospho-EGFR (Tyr1068), protein kinase B (Akt), phospho-Akt 
(Ser473), cleaved poly (ADP-ribose) polymerase (PARP), cleaved 
caspase-3, acetylated histone H3 (Lys27), BIM, and β-actin (Cell 
Signaling Technology) ; phospho-extracellular signal-regulated 
kinase 1 / 2 (ERK1 / 2 ; Thr202 / Tyr204), ERK1 / 2, and EGFR 
(R&D Systems). Blots were subsequently incubated with horse-
radish peroxidase-conjugated secondary antibodies specific to 
goat or rabbit immunoglobulin G, and the signals were detected 
by enhanced chemiluminescence using SuperSignal West Dura 
Extended Duration Substrate (Thermo Fisher Scientific).
Real-time reverse-transcriptase quantitative PCR (RT-qPCR)
Total cellular RNA was extracted from cells using 
ISOGEN (NIPPON GENE) in accordance with the manu-
facturer’s instructions. Reverse transcription was performed 
using SuperScript VILO cDNA synthesis Kit and Master 
Mix (Invitrogen). Expression of BIM mRNA was quantita-
tively measured by ViiA 7 Real-Time PCR System (Applied 
Biosystems) using the following primers : BIM exon 2A (for-
ward 5′-ATGGCAAAGCAACCTTCTGATG-3′ and reverse 
5′-GGCTCTGTCTGTAGGGAGGT-3 ′) ; BIM exon 3 (for-
ward 5′-CAATGGTAGTCATCCTAGAGG-3 ′ and reverse 
5′-GACAAAATGCTCAAGGAAGAGG-3 ′) ; BIM exon 4 
(forward 5′-TTCCATGAGGCAGGCTGAAC-3′ and reverse 
5′-CCTCCTTGCATAGTAAGCGTT-3 ′) ; and b-actin (for-
ward 5′-GGACTTCGAGCAAGAGATGG-3 ′ and reverse 
5′-AGCACTGTGTTGGCGTACAG-3′).
Staining for live cells and dead cells
Cell death induced by the drugs was determined through the 
use of Fluoroskan AscentTM FL (Thermo Fisher Scientific) using 
the Live or Dead cell viability Assay Kit (AAT Bioquest Inc, 
Sunnyvale, CA), which detected and quantified living cells with 
CellbriteTM Orange at 630 nm and apoptotic cells with BlueTM 
DCS1 at 420 nm using the microplate reader. 
Subcutaneous xenograft models
Male BALB / cAJcl-nu / nu mice, aged 5 to 6 weeks, were 
obtained from CLEA Japan Inc., and subcutaneously injected 
with cultured tumor cells (5 × 106 cells / 0.1 mL) into their flanks. 
Once the tumor volume reached 100 to 200 mm3, the mice were 
randomized and treated once daily with gefitinib and / or re-
sminostat. Each tumor was two-dimensionally measured, and 
the volume was calculated using the following formula : tumor 
volume (mm3) = 1 / 2 × length (mm) × width (mm)2. The study 
protocol was approved by the Ethics Committee on the Use of 
Laboratory Animals and the Advanced Science Research Cen-
ter, Kanazawa University, Kanazawa, Japan.
RESULTS
Resminostat upregulates BIM expression in EGFR-mutant NSCLC 
cell lines harboring BIM deletion polymorphism
We first examined the BIM-intron2 deletion polymorphism in 
EGFR-mutant NSCLC cell lines by PCR. PC-9 cells had wild-
type alleles with a PCR product of 4.2 kb. Consistent with a 
previous report (16, 26), PC-3 cells were heterozygous for BIM 
deletion polymorphism, as evident from the PCR products of 
4.2 kb (wild-type) and 1.3 kb (2.9 kb deletion polymorphism). 
PC-9BIM i2-/- cells had only deletion allele with a PCR product 
size of 1.3 kb. Western blot analysis revealed the markedly lower 
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expression of the major proapoptotic BIM protein (BIMEL) in 
PC-3 and PC-9BIM i2-/- cells than in PC-9 cells (Fig. 1A). We have 
previously reported that the HDAC inhibitor vorinostat upregu-
lates the level of acetylated histone H3 and BIM with the BH3 
domain in EGFR-mutated NSCLC cells heterozygous for BIM de-
letion (16). In line with this observation, we found that vorinostat 
dose-dependently increased the expression of acetylated histone 
H3 and BIM with the BH3 domain in PC-9BIM i2-/- cells (Fig. 1B) 
homozygous for BIM deletion polymorphism as well as in PC-3 
cells (Fig. 1C). Under same experimental conditions, resminostat 
increased the expression of acetylated histone H3 and BIM with 
the BH3 domain (BIMEL, BIML, and BIMS) in PC-9BIM i2-/- (Fig. 
1D) and PC-3 (Fig. 1E) cells in a dose-dependent manner. These 
results indicate that resminostat could upregulate the expres-
sion of the pro-apoptotic BIM protein in EGFR-mutated NSCLC 
cells that are either heterozygous or homozygous for BIM deletion 
polymorphism.
Resminostat upregulates BIM expression and efficiently induces 
apoptotic proteins in combination with EGFR-TKIs
We investigated whether the addition of resminostat to 
EGFR-TKIs results in the induction of apoptosis of EGFR-mu-
tant NSCLC cells homozygous for BIM deletion polymorphism. 
In parental PC-9 cells, gefitinib inhibited the phosphorylation 
of EGFR and the downstream molecules (AKT and ERK), 
increased the expression of the major pro-apoptotic BIM iso-
form (BIMEL), and induced the expression of apoptotic markers 
(cleaved caspase-3 and cleaved PARP) (Fig. 2A). On the contrary, 
while gefitinib inhibited the phosphorylation of EGFR and down-
stream molecules (AKT and ERK), it had minimal effects on the 
expression of BIMEL and apoptotic markers in PC-9BIM i2-/- cells 
(Fig. 2A). However, the combination of resminostat and gefitinib 
markedly increased the expression of BIMEL as well as the apop-
tosis markers cleaved caspase-3 and cleaved PARP (Fig. 2A). 
Figure 1.　Resminostat upregulates BIM expression in EGFR-mutant NSCLC cell lines harboring BIM deletion polymorphism
A, top, PCR products from three EGFR-mutated NSCLC cell lines generated by primers flanking the deletion regions. The PCR 
products of 4.2 and 1.3 kb correspond to the alleles without and with deletion, respectively, in the presence of both products, 
indicating the heterozygosity of the deletion polymorphism. Bottom, the level of the expression of the products BIMEL, BIML, and 
BIMS in each line. B-E, PC-9BIM i2-/- cells and PC-3 cells were incubated with serial dilutions of vorinostat (B, C) or resminostat (D, 
E) for 24 h. The cell lysates were harvested and the indicated proteins were analyzed by western blotting.
Figure 2.　Resminostat upregulates BIM expression and efficiently induces pro-apoptotic markers in combination with EGFR-TKIs
A, PC-9 and PC-9BIM i2-/- cells were incubated with gefitinib (1 µM) and / or resminostat (5 µM) for 12 h. The cell lysates were harvested 
and the indicated proteins were analyzed by western blotting. B, PC-9 GXR and PC-9BIM i2-/- GR cells were incubated with osimertinib 
(1 µM) and / or resminostat (5 µM) for 12 h. The cell lysates were harvested and the indicated proteins were determined by western 
blotting.
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Similar results were obtained when resminostat was combined 
with the third-generation EGFR-TKI osimertinib (Fig. 2B).
In PC-9 GXR cells with EGFR-T790M mutation, osimertinib 
inhibited the phosphorylation of EGFR and the downstream 
molecules AKT and ERK, increased the level of BIMEL, and in-
duced the expression of cleaved caspase-3 and cleaved PARP. PC-
9BIM i2-/- GR cells were positive for EGFR-T790M and resistant 
to gefitinib, and were derived following continuous exposure to 
gefitinib. In PC-9BIM i2-/- GR cells, osimertinib inhibited the phos-
phorylation of EGFR and the downstream molecules but mini-
mally increased the expression of BIMEL and apoptotic markers 
(Fig. 2C). However, the combination of resminostat and osimerti-
nib increased the expression of BIMEL as well as the apoptosis 
markers cleaved caspase-3 and cleaved PARP (Fig. 2C). 
We further evaluated whether resminostat combined with 
EGFR-TKI induced apoptosis by cytochemical staining for live 
cells (CellbriteTM Orange-positive) and apoptotic cells (BlueTM 
DCS1-positive). Gefitinib remarkably increased the number of 
apoptotic cells in PC-9 cells but not PC-9BIM i2-/- cells. Under 
these experimental conditions, gefitinib combined with re-
sminostat discernibly increased the number of apoptotic cells in 
PC-9BIM i2-/- cells (Fig. 3). These results indicate that resminostat 
upregulates BIM expression and efficiently induces apoptotic in 
combination with EGFR-TKIs.
Resminostat induces apoptosis of PC-9BIM i2−/− cells through the 
upregulation of BIM expression
To investigate whether the induction of apoptosis with the 
combined use of resminostat and EGFR-TKIs relies on the 
expression of BIM protein, PC-9BIM i2-/- cells were transfected 
with BIM-specific siRNA and then treated with resminostat and 
gefitinib for 48 h. We found that the knockdown of BIM protein 
expression mediated by BIM-specific siRNA resulted in the 
abrogation of apoptosis, as evident from the absence of cleaved 
PARP in resminostat- and gefitinib-treated PC-9BIM i2-/- cells 
(Fig. 4A). Analysis of BIM transcripts revealed that resminostat 
alone induced BIM mRNA expression, and this effect was en-
hanced in the presence of gefitinib. Moreover, the combination of 
resminostat and gefitinib preferentially induced the expression 
of the transcripts containing exon 4 over those containing exon 
3 (Fig. 4B, C). These findings suggest that the combined use of 
resminostat and EGFR-TKIs results in the upregulation of the 
expression of the pro-apoptotic BIM protein and induction of 
apoptosis of EGFR-mutated NSCLC cells homozygous for BIM 
deletion polymorphism in vitro.
 
Resminostat combined with gefitinib regresses the growth of the 
tumors derived from EGFR-mutated NSCLC cells with homozygous 
BIM deletion polymorphism in vivo
We next examined the effect of the combination of gefitinib and 
resminostat on EGFR-mutated NSCLC cells homozygous for BIM 
deletion polymorphism in vivo. PC-9 and PC-9BIM i2-/- cells were 
subcutaneously implanted in mice to produce tumors. The mice 
were then treated with gefitinib, resminostat, or the combination 
of both. Gefitinib alone markedly reduced the volume of the xeno-
graft tumor induced by PC-9 cells (Fig. 5A). Although gefitinib 
monotherapy prevented the enlargement of the tumor produced 
by PC-9BIM i2-/- cells harboring homozygous BIM-intron2 deletion 
Figure 3.　Resminostat induces cell death in combination with EGFR-TKIs
A, PC-9 and PC-9BIM i2-/- cells were incubated with gefitinib (1 µM) and / or resminostat (5 µM) for 48 h. The resultant cells were 
stained using the Live or Dead cell viability Assay Kit (AAT Bioquest Inc, Sunnyvale, CA), which detected and quantified living cells 
with CellbriteTM Orange (Red) at 630 nm and apoptotic cells with BlueTM DCS1 (Blue). Bar = 100 µm B, The live cells and dead cells 
were counted in four representative area and the percentage of dead cells was shown. * P < 0.05 Student’s t-test. 
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Figure 4.　Resminostat induces apoptosis of PC-9BIM i2-/- cells through the upregulation of BIM expression
A, PC-9BIM i2-/- cells were transfected with BIM or control siRNA for 24 h before gefitinib (1 µM) and resminostat (3 µM) treatment 
for 48 h. B, PC-9BIM i2-/- cells were treated with gefitinib (1 µM) and / or resminostat (3 µM) for 12 h. The levels of various transcripts 
containing exon 2A, 3, or 4 are expressed after normalization to actin level. C, Ratio of exon 3-containing transcripts to exon 
4-containing transcripts in PC-9BIM i2-/- cells after treatment with each compound.
Figure 5.　Resminostat combined with gefitinib regresses the growth of the tumors derived from EGFR-mutated NSCLC cells with 
homozygous BIM deletion polymorphism in vivo
The antitumor activity of gefitinib and / or resminostat in mouse xenograft models of PC-9 and PC-9BIM i2-/- tumors. Nude mice 
bearing established tumors with PC-9 (A) or PC-9BIM i2-/- (B) cells were treated with 25 mg / kg gefitinib and / or 60 mg / kg resminostat 
once daily for 15 days. Tumor volume was measured using calipers on the indicated days. Mean ± SE of tumor volumes are shown 
for groups of 6 to 7 mice. C, The body weight of mice examined in A and B was evaluated. D, Tumors were harvested 4 h after four 
consecutive treatments with each compound, and the levels of protein in tumor lysates were detected by western blotting.
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polymorphism, we failed to observe complete tumor regression. 
This observation indicates the tolerance of PC-9BIM i2-/- cells 
to gefitinib in vivo. Resminostat monotherapy, on the contrary, 
slightly inhibited tumor growth but markedly reduced the tumor 
volume in combination with gefitinib (Fig. 5B). None of the mice 
treated with these agents showed any macroscopic adverse 
effects, including loss of body weight (Fig. 5C). To clarify the 
mechanisms underlying the effect of resminostat and gefitinib in 
vivo, we performed western blot analysis on tumor lysates. As a 
result, we found that gefitinib induced the cleavage of caspase-3 
in PC-9 tumors. In PC-9BIM i2-/- tumors, treatment with gefitinib 
or resminostat had no effect on caspase-3 cleavage, which was 
increased along with BIM expression following the combination 
treatment with both agents (Fig. 5D). These findings indicate 
that the combination of resminostat and gefitinib increases BIM 
protein expression and induces tumor cell apoptosis, resulting in 
the shrinkage of the tumors produced by EGFR-mutated NSCLC 
cells carrying homozygous BIM deletion polymorphism.
 
DISCUSSION
Drug tolerant cells, also called as drug persisters or minimal 
residual lesions at dormant state, serve as a reservoir for the 
development of acquired resistance (3). Tolerance to EGFR-TKIs 
is mediated by several mechanisms, including activation of in-
sulin-like growth factor receptor 1 (IGF-1R) (3), AXL (27), and 
Yes-associated protein (YAP) (28) and inactivation of BIM, in 
EGFR-mutated NSCLC cells. Treatment to circumvent drug tol-
erance is still under evaluation in clinical trials. Here, we show 
that resminostat could sensitize BIM deletion polymorphism-pos-
itive EGFR-mutated NSCLC cells to EGFR-TKI-induced apop-
tosis and that the combined use of resminostat and EGFR-TKI 
could reduce the volume of the tumor produced by BIM deletion 
polymorphism-positive EGFR-mutated NSCLC cells in vivo.
HDAC inhibitors increase the acetylation of histones and 
other proteins that results in the induction of chromatin remod-
eling, promotion of tumor suppressor gene transcription, and 
apoptosis, leading to antitumor effects (25). Clinically, the activ-
ity of HDAC inhibitors has been mainly demonstrated in hema-
tologic malignancies, including cutaneous T cell lymphoma and 
multiple myeloma (25). The activity of resminostat, an oral drug, 
is higher toward HDAC-1 and 3 (class I HDACs) and HDAC-6 
(class IIb HDAC) than toward HDAC8 (class I HDAC) (19). 
In the present study, we found that resminostat with HDAC3 
inhibitory activity circumvented the tolerance to apoptosis de-
veloped by BIM deletion polymorphism-positive EGFR-mutated 
NSCLC cells treated with EGFR-TKIs. This observation in the 
line with our previous finding that HDAC3 inhibition by HDAC 
inhibitors plays a crucial role in apoptosis induction through the 
promotion of transcription and modulation of alternative splicing 
to upregulate active BIM protein level in BIM deletion polymor-
phism-positive EGFR-mutated NSCLC cells (26). A phase I trial 
in Japanese patients with solid tumors demonstrated the drug 
safety ; the recommended dose for phase II study with resminos-
tat monotherapy was 800 mg once daily on days 1-5 biweekly 
(29). A phase II trial is currently ongoing to evaluate whether 
resminostat can serve as a maintenance treatment for patients 
with mycosis fungoides or Sézary syndrome after disease control 
with other systemic therapies (NCT02953301). 
Resminostat belongs a class of HDAC inhibitor that is called 
hydroxamic acid-based histone deacetylase inhibitor as same 
as vorinostat. However, the chemical structure of resminostat 
differs from that of vorinostat in detail (30). Actually, it was 
reported that a HDAC inhibitor interacted with a variety of 
histone and non-histone protein, and their profile of interacting 
proteins tends to be different for different HDAC inhibitors, and 
it was not depended on a class of HDAC inhibitor (31). It was 
also reported that mechanisms of antitumor effect of HDAC 
inhibitors may be different and depend on HDAC inhibitors (32). 
We speculated that the difference of the profile of interacting 
proteins may contribute to a difference of safety and efficacy 
profile of HDAC inhibitors. Therefore, we examined resminostat 
efficacy as a new HDAC inhibitor other than vorinostat that we 
previously reported the efficacy.
We have previously conducted investigator initiated trials for 
BIM deletion / EGFR mutation double-positive NSCLC patients 
to determine the safety of vorinostat-gefitinib combination 
and evaluate the pharmacodynamic biomarkers of vorinostat 
activity (17). We failed to notice any dose-limiting toxicity, and 
proposed 400 mg vorinostat as the recommended phase II dose. 
Although this was a phase I study with limited number of pa-
tients, the median PFS was 5.2 months (95% confidence interval 
1.4–15.7) ; the disease control rate at 6 weeks was 83.3% (10 / 12) 
in a previous heavily-treated patient population (17). Moreover, 
the analysis of peripheral blood mononuclear cells revealed that 
vorinostat preferentially induced the expression of BIM mRNA 
containing exon 4 over that containing exon 3, acetylated histone 
H3 protein, and pro-apoptotic BIMEL protein in 11 / 11, 10 / 11, 
and 5 / 11 patients, respectively (17). These data indicate that 
the BIM mRNA exon3 / exon4 ratio in PBMCs may be a useful 
pharmacodynamic marker for treatment (17). As osimertinib is 
recognized as one of standard first-line treatment for EGFR-mu-
tated NSCLC (2), the use of the combination of osimertinib and 
new-generation HDAC inhibitors, including resminostat, along 
with the monitoring of this pharmacodynamic marker may be 
worth testing in BIM deletion polymorphism-positive EGFR-mu-
tated NSCLC. 
In conclusion, resminostat with HDAC3 inhibitory activity 
could preferentially induce the expression of the pro-apoptotic 
BIM transcript containing exon 4 rather than the BIM tran-
script containing exon 3 ; it also increased pro-apoptotic BIM 
protein (BIMEL) level and stimulated apoptosis in vitro. In ad-
dition, the combined use of resminostat and gefitinib increased 
BIMEL protein level and induced apoptosis, thereby leading to 
a remarkable shrinkage of tumors produced by EGFR-mutated 
NSCLC with BIM deletion polymorphism. These findings sug-
gest the potential application of resminostat to circumvent toler-
ance to EGFR-TKIs associated with BIM deletion polymorphism.
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